CLOs on the Move

AgBiome

www.agbiome.com

 
AgBiome® partners with the microbial world to improve our planet. AgBiome discovers and develops innovative biological and trait products for crop protection. The proprietary GENESIS™ discovery platform efficiently captures diverse, unique microbes for agriculturally relevant applications, and screens them with industry-best assays for insect, disease, and nematode control. Through its commercial subsidiary, AgBiome develops and sells proprietary crop protection solutions. The first of these, Howler®, is a revolutionary fungicide for disease control in a broad variety of crops.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.agbiome.com
  • 104 T. W. Alexander Drive Building 18
    Research Triangle Park, NC USA 27709
  • Phone: 984.234.1472

Executives

Name Title Contact Details
Timothy Meigs
Chief Intellectual Property Counsel Profile
Christopher Matton
General Counsel Profile

Similar Companies

Aurora Biomed

Aurora Biomed is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

DNA Script

DNA Script was created to revolutionize DNA synthesis with enzymes` Our core R&D efforts have produced innovations in enzyme engineering, surface and nucleotide chemistries, and instrumentation` The integration of these innovations has resulted in SYNTAX™️, the world’s first benchtop DNA printer powered by enzymatic technology` With continued advancement and innovation, we believe DNA Script’s enzymatic DNA synthesis technology is poised to become the engine of genomics research and personalized medicine`

MeMed

MeMed is a host response, med-tech & bioconvergence company, offering innovative diagnostic host response tests that address complex clinical dilemmas & improve patient outcomes.

Chiasma

Chiasma improves the lives of patients by transforming injectable drugs into oral medications. The company`s proprietary, clinically validated Transient Permeability Enhancer (TPE®) technology enables intestinal absorption of molecules that previously had limited intestinal bioavailability. Chiasma focuses on peptide drugs, which serve a large market that is currently served only by injectables. Oral formulations offer numerous advantages, including consistent dosing and the elimination of administration site reactions. Chiasma’s lead investigational candidate, octreotide capsules, is being developed for the treatment of acromegaly.

EdiGENE

EdiGENE Corporation is an emerging biotech company focusing on developing transformative therapeutics for unmet medical needs using its proprietary technologies on CRISPR and protein engineering platforms. The company has a strong foundation on intellectual property licensed from the University of Tokyo.